LMR Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

LMR Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-450,000	Closed	-$59.4M	–	1740
2025 Q1	$59.4M	Buy	+450,000	New	+$56.1M	0.56%	26
2024 Q3	–	Sell	-25,000	Closed	-$1.71M	–	1589
2024 Q2	$1.71M	Sell	25,000 -3,500	-12%	-$243K	0.01%	572
2024 Q1	$1.97M	Sell	28,500 -115,200	-80%	-$7.92M	0.02%	549
2023 Q4	$10.3M	Buy	143,700 +55,800	+63%	+$3.21M	0.12%	196
2023 Q3	$4.58M	Buy	87,900 +43,400	+98%	+$2.53M	0.05%	263
2023 Q2	$2.82M	Buy	+44,500	New	+$2.77M	0.03%	310

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

LMR Partners's ITCI Position: Q2 2025 in Review

LMR Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 863,134 shares — an estimated $114M sold.

LMR Partners first reported a position in ITCI in Q4 2019 and held it in 12 quarters. The position peaked at $114M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

LMR Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
LMR Partners sold 863,134 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $114M.
LMR Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 12 quarters.
LMR Partners's Intra-Cellular Therapies Inc. position peaked at $114M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.